Cover Image
市場調查報告書

的醫藥品的預測與市場分析PharmaPoint:重度憂鬱症 - EU5個國家

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 305471
出版日期 內容資訊 英文 193 Pages
訂單完成後即時交付
價格
Back to Top
的醫藥品的預測與市場分析PharmaPoint:重度憂鬱症 - EU5個國家 PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
出版日期: 2014年05月30日 內容資訊: 英文 193 Pages
簡介

重度憂鬱症是全球最常見的精神疾病之一。該市場的競爭激烈,有超過30種產品治療藥正在上市。在主要產品的專利到期、最終階段的開發平台產品投入市場的當下,市場正在大大變動中。預測法國市場將會縮小,西班牙則有7個位於最終階段的開發中產品即將上市。

本報告提供EU主要5個國家重度憂鬱症的治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀及亞型
  • 預後
  • QOL

第4章 疾病的管理

  • 症狀和治療概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 產品簡介:領導品牌,選擇性血清素再吸收抑制劑
  • 產品簡介:領導品牌,血清素-去甲腎上腺素再吸收抑制劑
  • 產品簡介:領導品牌,其他抗憂鬱症藥
  • 產品簡介:領導品牌,抗精神藥
  • 其他的治療藥物級

第6章 機會及未滿足需求

  • 概要
  • 更有效的藥物療法
  • 更良好的副作用簡介
  • 效果快速的抗憂鬱效果
  • 個人化醫療的方法

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 其他開發中的藥物

第8章 市場預測

  • 全球
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第9章 附錄

圖表

目錄
Product Code: GDHC243CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The value of the depression market in France is expected to fall following patent expiries for Lundbeck's Lexapro in 2014, Eli Lilly's Cymbalta in 2014, Otsuka Pharmaceutical/BMS's Abilify in 2014, and AstraZeneca's Seroquel XR in 2017. GlobalData estimates the drug sales for MDD in Germany were approximately $236.7m in 2013. GlobalData expects Eli Lilly's Cymbalta and Lundbeck's Brintellix to be the top-selling products by the end of the forecast period in Italy. GlobalData anticipates seven products in the late-stage pipeline to enter the MDD market in Spain during the forecast period: four adjunctive therapies, and three other antidepressant therapies. If physicians in the UK become convinced from experience in clinical practice that Brintellix offers improvements in cognitive function, Lundbeck will be able to differentiate Brintellix from other available SSRI and SNRI treatments and subsequently drive higher patient share.

Scope

  • Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Major depressive disorder market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. France
  • 4.3. Germany
  • 4.4. Italy
  • 4.5. Spain
  • 4.6. UK

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors
    • 5.2.1. Lexapro (Escitalopram)
    • 5.2.2. Other Selective Serotonin Reuptake Inhibitors
  • 5.3. Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors
    • 5.3.1. Effexor (Venlafaxine)
    • 5.3.2. Cymbalta (Duloxetine)
    • 5.3.3. Pristiq (Desvenlafaxine)
    • 5.3.4. Savella (Milnacipran)
  • 5.4. Product Profiles: Major Brands, Other Antidepressants
    • 5.4.1. Norepinephrine-Dopamine Reuptake Inhibitors
    • 5.4.2. Noradrenaline and Specific Serotonergic Antidepressants
    • 5.4.3. Monoamine Oxidase Inhibitors
    • 5.4.4. Tricyclic Antidepressants
    • 5.4.5. Brintellix (Vortioxetine)
  • 5.5. Product Profiles: Major Brands, Antipsychotics
    • 5.5.1. Abilify (Aripiprazole)
    • 5.5.2. Seroquel XR (Quetiapine)
  • 5.6. Other Therapeutic Classes

6. Unmet Needs and Opportunities

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunities
  • 6.3. More Favorable Side Effect Profiles
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunities
  • 6.4. Rapid Onset of Antidepressant Effects
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunities
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunities

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Brexpiprazole (OPC-34712)
    • 7.2.2. Cariprazine (RGH-188)
    • 7.2.3. ALKS-5461
    • 7.2.4. Amitifadine (EB-1010)
    • 7.2.5. GLYX-13
    • 7.2.6. Tedatioxetine (Lu AA24530)
    • 7.2.7. ETS6103
  • 7.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Global
    • 8.1.1. Drivers and Barriers - Global Issues
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. UK
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed MDD Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Directors
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 5EU, 2013
  • Table 6: Country Profile - France
  • Table 7: Country Profile - Germany
  • Table 8: Country Profile - Italy
  • Table 9: Country Profile - Spain
  • Table 10: Country Profile - UK
  • Table 11: Leading Treatments for MDD, 2013
  • Table 12: Product Profile - Lexapro
  • Table 13: Safety of Lexapro - Five Most Frequently Reported Adverse Events
  • Table 14: Lexapro SWOT Analysis, 2014
  • Table 15: Relative Frequency of Common Adverse Effects for Different SSRIs
  • Table 16: Product Profile - Effexor
  • Table 17: Effexor SWOT Analysis, 2014
  • Table 18: Product Profile - Cymbalta
  • Table 19: Cymbalta SWOT Analysis, 2023
  • Table 20: Product Profile - Pristiq
  • Table 21: Efficacy of Pristiq in short-term studies
  • Table 22: Pristiq SWOT Analysis, 2014
  • Table 23: Product Profile - Savella
  • Table 24: Savella SWOT Analysis, 2014
  • Table 25: Product Profile - Bupropion
  • Table 26: Safety of Bupropion - Five Most Frequently Reported Adverse Events
  • Table 27: Bupropion SWOT Analysis, 2014
  • Table 28: Product Profile - Mirtazapine
  • Table 29: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events
  • Table 30: Mirtazapine SWOT Analysis, 2014
  • Table 31: MAOI SWOT Analysis, 2014
  • Table 32: TCAs SWOT Analysis, 2014
  • Table 33: Product Profile - Brintellix
  • Table 34: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials
  • Table 35: Safety of Brintellix - Five Most Frequently Reported Adverse Events
  • Table 36: Brintellix SWOT Analysis, 2014
  • Table 37: Product Profile - Abilify
  • Table 38: Safety of Abilify - Five Most Frequently Reported Adverse Events
  • Table 39: Abilify SWOT Analysis, 2014
  • Table 40: Product Profile - Seroquel XR
  • Table 41: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants
  • Table 42: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events
  • Table 43: Seroquel XR SWOT Analysis, 2014
  • Table 44: Summary of Minor Therapeutic Classes in MDD, 2013
  • Table 45: Unmet Needs and Opportunities in MDD
  • Table 46: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 47: Product Profile - Brexpiprazole
  • Table 48: Safety of Brexpiprazole - Most Frequently Reported Adverse Events
  • Table 49: Brexpiprazole SWOT Analysis, 2014
  • Table 50: Product Profile - Cariprazine
  • Table 51: Cariprazine SWOT Analysis, 2014
  • Table 52: Product Profile - ALKS-5461
  • Table 53: ALKS-5461 SWOT Analysis, 2014
  • Table 54: Product Profile - Amitifadine
  • Table 55: Amitifadine SWOT Analysis, 2014
  • Table 56: Product Profile - GLYX-13
  • Table 57: GLYX-13 SWOT Analysis, 2014
  • Table 58: Product Profile - Tedatioxetine
  • Table 59: Tedatioxetine SWOT Analysis, 2014
  • Table 60: Product Profile - ETS6103
  • Table 61: ETS6103 SWOT Analysis, 2014
  • Table 62: Drugs in Development for MDD, 2014
  • Table 63: MDD Market - Drivers and Barriers, 2013-2023
  • Table 64: Sales Forecasts ($m) for MDD in France, 2013-2023
  • Table 65: Key Events Impacting Sales for MDD in France, 2013-2023
  • Table 66: MDD Market in France - Drivers and Barriers, 2013-2023
  • Table 67: Sales Forecasts ($m) for MDD in Germany, 2013-2023
  • Table 68: Key Events Impacting Sales for MDD in Germany, 2013-2023
  • Table 69: MDD Market in Germany - Drivers and Barriers, 2013-2023
  • Table 70: Sales Forecasts ($m) for MDD in Italy, 2013-2023
  • Table 71: Key Events Impacting Sales for MDD in Italy, 2013-2023
  • Table 72: MDD Market in Italy - Drivers and Barriers, 2013-2023
  • Table 73: Sales Forecasts ($m) for MDD in Spain, 2013-2023
  • Table 74: Key Events Impacting Sales for MDD in Spain, 2013-2023
  • Table 75: MDD Market in Spain - Drivers and Barriers, 2013-2023
  • Table 76: Sales Forecasts ($m) for MDD in the UK, 2013-2023
  • Table 77: Key Events Impacting Sales for MDD in the UK, 2013-2023
  • Table 78: MDD Market in the UK - Drivers and Barriers, 2013-2023
  • Table 79: Key Launch Dates
  • Table 80: Key Patent Expiries
  • Table 81: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of Brexpiprazole
  • Figure 7: Clinical and Commercial Positioning of Cariprazine
  • Figure 8: Clinical and Commercial Positioning of ALKS-5461
  • Figure 9: Clinical and Commercial Positioning of Amitifadine
  • Figure 10: Clinical and Commercial Positioning of GLYX-13
  • Figure 11: Clinical and Commercial Positioning of Tedatioxetine
  • Figure 12: Clinical and Commercial Positioning of ETS6103
  • Figure 13: Sales for MDD in France by Drug Class, 2013-2023
  • Figure 14: Sales for MDD in Germany by Drug Class, 2013-2023
  • Figure 15: Sales for MDD in Italy by Drug Class, 2013-2023
  • Figure 16: Sales for MDD in Spain by Drug Class, 2013-2023
  • Figure 17: Sales for MDD in the UK by Drug Class, 2013-2023
Back to Top